Optical biomodule for detection of diseases at an early onset

US2025093345A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2025093345-A1
Application numberUS-202418831208-A
CountryUS
Kind codeA1
Filing dateSep 14, 2024
Priority dateSep 28, 2019
Publication dateMar 20, 2025
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

An optical biomodule for detecting a disease specific biomarker(s) at an early stage, utilizing enhanced fluorescence emission (due to integration of three-dimensional (3-D) structures in a fluidic container) upon chemical binding/coupling of a disease specific biomarker(s) with its corresponding disease specific biomarker binder(s)-coupled with a fluorophore(s) positioned horizontally within a geometrical area (that includes a center region or a middle region) is disclosed. Furthermore, a corresponding disease specific biomarker binder(s) may include an amplifying chemical structure/sequence. The three-dimensional (3-D) structure(s) may be coupled with an optical resonator and/or a photonic crystal (PC) and/or a metamaterial and/or a metamaterial of Epsilon-Near-Zero (ENZ) of a suitable wavelength range.

First claim

Opening claim text (preview).

I claim: 1 . An optical biomodule comprising: (a) a fluidic container; wherein the fluidic container comprises one or more (i) materials or (ii) first metamaterials, wherein the fluidic container further comprises a first biomarker binder and/or a second biomarker binder, wherein the first biomarker binder comprises one or more segments, wherein the second biomarker binder comprises one or more segments, wherein the first biomarker binder is coupled with one or more first fluorophores, wherein the second biomarker binder is coupled with one or more second fluorophores, wherein the first biomarker binder binds or couples with a biomarker, wherein the second biomarker binder binds or couples with the biomarker, wherein the fluidic container further comprises a plurality of three-dimensional (3-D) structures, wherein the three-dimensional (3-D) structures are spaced or arranged in a one-dimensional (1-D) array or in a two-dimensional (2-D) array, wherein a pitch or a duty cycle of the one-dimensional (1-D) array or the two-dimensional (2-D) array of the three-dimensional (3-D) structures is varied for an enhancement of a fluorescence emission or a light signal, wherein at least (i) one of the one or more first fluorophores or (ii) one of the one or more second fluorophores is within a geometrical area in a horizontal plane, wherein the geometrical area in the horizontal plane includes a center region or a middle region in the horizontal plane, wherein the center region or the middle region in the horizontal plane is within a gap in the horizontal plane, wherein the geometrical area in the horizontal plane is defined by at least the gap in the horizontal plane, wherein the gap in the horizontal plane is defined by at least one of the one or more three-dimensional (3-D) structures, (b) a light source for inducing the fluorescence emission or the light signal; and (c) a device for detecting the fluorescence emission or the light signal, wherein the device comprises (i) a photodiode or (ii) a light sensor. 2 . The optical biomodule according to claim 1 , wherein the fluidic container further comprises a substrate or a well or an optical waveguide. 3 . The optical biomodule according to claim 1 , wherein the fluidic container (i) further comprises periodic layers of the one or more materials or (ii) coupled with a microfluidic chip, wherein the microfluidic chip comprises one or more microfluidic channels. 4 . The optical biomodule according to claim 1 , wherein the first biomarker binder or the second biomarker binder comprises (i) an amplifier that includes nucleotides or (ii) a chemical structure that is coupled with a metal and/or a dielectric material, wherein the amplifier is a linear amplifier or a nonlinear amplifier. 5 . The optical biomodule according to claim 1 , wherein at least one of the three-dimensional (3-D) structures is coupled with (i) a photonic crystal (PC) or (ii) a second metamaterial, wherein the second metamaterial is an Epsilon-Near-Zero (ENZ). 6 . The optical biomodule according to claim 1 , wherein at least one of the three-dimensional (3-D) structures is coupled with a third metamaterial, wherein the third metamaterial is a hyperbolic metamaterial (HMM). 7 . The optical biomodule according to claim 6 , wherein the third metamaterial is coupled with one or more nanoscaled holes or gratings. 8 . The optical biomodule according to claim 1 , wherein at least one of the three-dimensional (3-D) structures is coupled with an optical resonator. 9 . The optical biomodule according to claim 1 , wherein at least one of the three-dimensional (3-D) structures is within a recessed closed cavity or within a recessed open cavity. 10 . The optical biomodule according to claim 1 , wherein at least one of the three-dimensional (3-D) structures is on a substrate or within a well or within an optical waveguide. 11 . The optical biomodule according to claim 1 , wherein at least one of the three-dimensional (3-D) structures is coupled or integrated with the light source, wherein the light source comprises a nanoscaled light source or quantum-entangled photons, wherein a maximum dimension of the nanoscaled light source is less than 1000 nanometers. 12 . The optical biomodule according to claim 1 , wherein the light source is selected from the group consisting of a quantum dot laser, a squeezed light laser, a light source based on a two-dimensional material, a chip-scaled titanium:sapphire-on-insulator waveguide laser and a Bose-Einstein condensate (BEC) coupled light source, wherein the chip-scaled titanium:sapphire-on-insulator waveguide laser is optically pumped. 13 . The optical biomodule according to claim 1 , wherein the light sources comprise a first coherent light source and a second coherent light source, wherein a light beam of the first coherent light source has an open toroidal shape in cross-section, wherein the first coherent light source and the second coherent light source are activated simultaneously. 14 . The optical biomodule according to claim 1 , wherein the biomarker or the first biomarker binder or the second biomarker binder is trapped by a trap, wherein the trap comprises (i) one or more nanoscaled focusing elements or one or more nanoscaled holes and (ii) a laser. 15 . The optical biomodule according to claim 1 , further comprises a spectrophotometer for detecting a Raman signal. 16 . The optical biomodule according to claim 15 , wherein the spectrophotometer is coupled with (i) a refractive optical element and/or (ii) a reflective optical element and/or (iii) a light concentrator. 17 . The optical biomodule according to claim 15 , wherein the spectrophotometer is communicatively interfaced with a set of computer implemented instructions in artificial intelligence or an artificial neural network (ANN), wherein the set of computer implemented instructions is stored in one or more non-transitory storage media. 18 . An optical biomodule comprising: (a) a fluidic container; wherein the fluidic container comprises one or more (i) materials or (ii) first metamaterials, wherein the fluidic container further comprises a first biomarker binder and/or a second biomarker binder, wherein the first biomarker binder comprises one or more segments, wherein the second biomarker binder comprises one or more segments, wherein the first biomarker binder is coupled with one or more first fluorophores, wherein the second biomarker binder is coupled with one or more second fluorophores, wherein the first biomarker binder binds or couples with a biomarker, wherein the second biomarker binder binds or couples with the biomarker, wherein the first biomarker binder or the second biomarker binder comprises (i) an amplifier that includes nucleotides or (ii) a chemical structure that is coupled with a metal and/or a dielectric material, wherein the amplifier is a linear amplifier or a nonlinear amplifier, wherein the fluidic container further comprises a plurality of three-dimensional (3-D) structures, wherein the three-dimensional (3-D) structures are spaced or arranged in a one-dimensional (1-D) array or in a two-dimensional (2-D) array, wherein a pitch or a duty cycle of the one-dimensional (1-D) array or the two-dimensional (2-D) array of the three-dimensional (3-D) structures is varied for an enhancement of a fluorescence emission or a light signal, wherein at least (i) one of the one or more first fluorophores or (ii) one of the one or more second fluorophores is within a geometrical area in a

Assignees

Inventors

Classifications

  • graphically representing goods, e.g. 3D product representation · CPC title

  • Microscopic objects, e.g. biological cells or cellular parts · CPC title

  • Coherent sources; lasers · CPC title

  • Non-radioactive isotope labels, e.g. for detection by mass spectrometry · CPC title

  • Analytical elements · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2025093345A1 cover?
An optical biomodule for detecting a disease specific biomarker(s) at an early stage, utilizing enhanced fluorescence emission (due to integration of three-dimensional (3-D) structures in a fluidic container) upon chemical binding/coupling of a disease specific biomarker(s) with its corresponding disease specific biomarker binder(s)-coupled with a fluorophore(s) positioned horizontally within a…
Who is the assignee on this patent?
Mazed Mohammad A
What technology area does this patent fall under?
Primary CPC classification G01N33/5436. Mapped technology areas include Physics.
When was this patent published?
Publication date Thu Mar 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).